Tocilizumab Dose Tapering Based on a Model-Based Algorithm is Feasible in Clinical Practice: A Short Communication

Area of Science:

• Pharmacology
• Rheumatology
• Clinical Trials

Background:

• Tocilizumab (TCZ) dosing in rheumatoid arthritis (RA) shows variable serum concentrations, often exceeding therapeutic levels.
• An exposure-response relationship for TCZ is established, suggesting potential for dose optimization.
• No prior clinical trials have investigated TCZ tapering in RA patients.

Purpose of the Study:

• To assess the feasibility of tapering intravenous (IV) tocilizumab in RA patients using a pharmacokinetic model-based algorithm.
• To evaluate the safety and efficacy of concentration-guided TCZ dose reduction.

Main Methods:

• A 24-week, double-blind, randomized controlled trial was conducted.
• RA patients on stable TCZ therapy were randomized to either therapeutic drug monitoring (TDM) for dose tapering or a standard 8 mg/kg dose.
• The TDM group aimed for a target TCZ concentration of 4-6 mg/L using a model-based algorithm.

Main Results:

• The study demonstrated feasibility, with patients showing a positive attitude towards TDM.
• TCZ trough concentrations significantly decreased in the TDM group compared to the standard dose group.
• No patients in the TDM group achieved the target 4-6 mg/L range; concentrations were 1.6 and 1.5 mg/L for those completing follow-up.
• No significant differences in RA disease activity were observed between groups.

Conclusions:

• This is the first study to demonstrate the feasibility of applying a pharmacokinetic model-based dose-reduction algorithm for TCZ in clinical practice.
• The current algorithm requires further optimization before large-scale implementation.
• Concentration-guided TCZ tapering shows potential for managing RA treatment.